<DOC>
	<DOC>NCT01537653</DOC>
	<brief_summary>Primary Objective: Assess the safety and tolerability of SAR231893 (REGN668) after ascending single subcutaneous (SC) doses in healthy Japanese adult male subjects Secondary Objectives: Assess the following parameters after ascending single SC doses in healthy Japanese adult male subjects - The pharmacokinetics of SAR231893 (REGN668) - The immunogenicity of SAR231893 (REGN668) - Exploratory analyses of the pharmacodynamics of SAR231893 (REGN668)</brief_summary>
	<brief_title>Safety, Tolerability and Pharmacokinetics of SAR231893 (REGN668) in Healthy Japanese Adult Male Subjects</brief_title>
	<detailed_description>Total duration of the study period per subject is 11 weeks broken down as follows: Screening period = 2 to 21 days Treatment period = 57 days, including 1 treatment day</detailed_description>
	<criteria>Inclusion criteria: Japanese adult male subjects, between 20 and 45 years of age, inclusive. Body weight between 50.0 and 95.0 kg, inclusive, body mass index between 18.0 and 28.0 kg/m2, inclusive. Certified as healthy by a comprehensive clinical assessment. Having given written informed consent prior to undertaking any studyrelated procedure. Exclusion criteria: Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, or infectious disease, or signs of acute illness. Any subject who cannot prohibit intensive physical activity throughout the study duration. Positive result on any of the following tests: hepatitis B surface (HBs Ag) antigen, antihepatitis B core antibodies (antiHBc Ab), antihepatitis C virus (antiHCV) antibodies, human immunodeficiency virus (HIV) antigen and antibodies. Positive result on urine drug screen (amphetamines/methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates). Serum alcohol level over the upper limit of normal range (ULN). Previous exposure to any therapeutic or investigational biological agent. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>